Mass Tort Lead Generation: How Claimant Acquisition Works From First Ad to Signed Retainer
A managing partner called us in February. Six months. $180,000 in mass tort lead spend. Two vendors. Twenty dockets covered between them. His AFFF intake had a 31% contact rate. His Roundup intake had a 22% contact rate. He wanted to know why the gap was so wide.
The Firm That Spent $180,000 and Got “Diagnosed”
That’s it. One word. “Diagnosed.”
No product confirmed. No diagnosis code. No exposure dates. No SOL verification against the specific docket. No documentation of what question was asked or what answer qualified the claimant.
His vendor had run one funnel for all twenty dockets and labeled the output mass tort leads.
He had no idea. And he’s not unusual. Most law firms buying mass tort leads have never seen the funnel that generated them. Don’t know what questions were asked. Don’t know whether those questions match their docket’s actual criteria. Don’t know whether the SOL was verified against the right framework.
This page fixes that. Here’s exactly how mass tort claimant acquisition works — from the first ad impression to the qualified lead in your CRM.
Mass Tort Lead Generation Is Not PI Lead Generation With Different Creative
The biggest mistake law firms make when entering mass tort is treating it like a more expensive version of MVA lead buying.
It is not.
Three structural differences make mass tort categorically different — and if you don’t understand all three, you will buy the wrong product, pay the wrong price, and get burned in the same way as the firm above.
Difference 1: Every Docket Is a Different Product
An MVA funnel confirms accident, injury, fault, SOL, and representation. That same logic works for every car accident lead regardless of case type. Adjust slightly for geography. The framework is consistent.
Mass tort cannot work this way.
A Roundup claimant must confirm glyphosate herbicide use over a minimum period and a non-Hodgkin’s lymphoma diagnosis.
An AFFF claimant must confirm firefighting foam exposure at a military installation and a PFAS-linked cancer — bladder, kidney, testicular, thyroid.
A Depo-Provera claimant must confirm injectable contraceptive use over a minimum duration and a meningioma brain tumor — not other brain tumors. That specific diagnosis.
These are three different screening protocols applied to three different plaintiff populations. A vendor running one “mass tort” funnel is not doing mass tort lead generation. They are collecting unqualified responses and attaching docket labels to them.
Your intake team figures this out — after you’ve already paid.
Difference 2: The SOL Logic Is Docket-Specific
In MVA, the SOL is a fixed window from the incident date. Standard PI logic applies.
In mass tort, most dockets run on the discovery rule. The window opens from the date the plaintiff knew — or should have known — that their injury was caused by the product. Not from the exposure date.
A person diagnosed with mesothelioma in 2024 from asbestos exposure in 1975 is not SOL-barred. A Camp Lejeune claimant who only learned their illness was connected to contaminated water last year is not SOL-barred despite the exposure occurring forty years ago.
Dockets also carry independent federal filing deadlines set by MDL courts that are separate from state SOL rules. Shorter in some cases. Earlier.
A vendor applying standard PI SOL logic to mass tort is going to reject viable claimants and deliver worthless ones. The SOL verification has to be docket-specific.
Difference 3: The Acquisition Window Closes
MVA demand is evergreen. Car accidents happen every day. You can buy MVA leads indefinitely.
Mass tort demand is time-bounded. Each docket is strongest in the active phase of MDL litigation — after enough discovery to establish plaintiff value, before the plaintiff class is largely aggregated. As a docket matures, acquisition costs rise, buyer demand consolidates, and the campaign closes.
The firms that win in mass tort get in early. By the time a docket is widely known and most operators are running it, the best economics have already passed.
The Four Stages Every Qualified Mass Tort Lead Must Survive
This is the framework. Call it The Docket-Specific Acquisition Stack.
Four stages. Every lead. No exceptions. What changes per docket is the criteria inside each stage — not the stages themselves.
The campaign runs on Meta, Google, or programmatic channels. The creative, the targeting, and the landing page are built for the specific docket’s plaintiff population.
AFFF campaigns target firefighters, military personnel, and first responders. Not the general population.
Roundup campaigns target agricultural workers, landscapers, and home gardeners with documented heavy herbicide use.
Hair relaxer campaigns target women with consistent long-term product use. Not every woman on Meta.
The audiences don’t overlap. The creatives don’t overlap. The landing pages don’t overlap. A vendor who runs one ad for all dockets is generating awareness leads, not plaintiff leads.
Meta classifies mass tort advertising under special ad categories with restricted targeting and specific consent language requirements. Operators who don’t understand this get their accounts shut down in 30-60 days. If your vendor has had multiple ad account disruptions — that’s the reason.
This is where real mass tort lead generation separates from generic form collection.
A properly built qualification form for each docket confirms:
A claimant who fails any of these gates is not delivered. They are not rerouted to a different docket. They are filtered out.
Docket reassignment after the fact is a sign that a vendor is protecting their volume, not your qualification standards. “This claimant didn’t qualify for Roundup so we sent them as an Ozempic lead” is not a feature. It’s a failure disclosed as a service.
After completing the qualification form, the claimant receives a one-time passcode via SMS. They enter the code to complete their submission.
This confirms the phone number is real, active, and in the claimant’s possession at submission.
In mass tort specifically, this matters for a reason beyond contact rate. Mass tort intake involves medical record review and additional qualification verification before a retainer is signed. The gap between first contact and signed retainer is longer than in MVA. During that window, a disconnected or invalid phone number is a complete dead end.
OTP also creates compliance documentation. The verification timestamp and carrier session data become part of the permanent lead record — alongside the TrustedForm certificate and Jornaya lead ID. For mass tort buyers who require compliance documentation as a contract condition, this is not optional. It’s the infrastructure that separates a vendor worth working with from one who creates legal exposure.
The qualified, verified lead goes to one firm — yours — with the complete qualification record. Every field the claimant answered ships with the lead. Product use confirmed. Exposure dates. Qualifying diagnosis. SOL verification. Representation status. OTP timestamp. TrustedForm certificate. Jornaya lead ID.
Your intake team reads the docket-specific case facts before making the first call. They know whether the claimant has a qualifying AFFF cancer diagnosis and what their exposure history is before the phone rings.
This is categorically different from a name, a phone number, and a docket label.
The lead goes to one firm. It is not simultaneously delivered to other buyers, re-queued after five minutes of non-response, or made available to other firms at any price. At $500+ per lead with case values of $50,000 to $500,000+, shared delivery is not an economic option.
The Compliance Stack: Why Mass Tort Needs Three Layers
TCPA exposure in mass tort is higher than in standard PI. The reason is consent specificity.
Under current rules, a claimant must give one-to-one consent to be contacted by a specific entity. If a lead goes to one firm with a consent form naming that firm, the consent is clean. If a lead is shared with five firms, all five must be named in the consent form — or the contact may violate TCPA.
Shared mass tort leads create compliance complexity that exclusive leads avoid entirely.
Three documentation layers protect the firm:
For mass tort, all three are the standard. Not a premium tier. The standard.
The Economics: What Docket-Specific Qualification Does to Your CPR
Mass tort leads run $450–$600+ per lead. Most firms fixate on that number. Wrong metric.
The relevant metric is cost per signed retainer.
Here’s the math.
Intake re-qualifies on the phone because the form didn’t. Disqualification rate: 40-50%. Effective cost per qualified lead: $900–$1,000. Close rate: 12%. Cost per signed retainer: $7,500–$8,300.
Docket-specific leads at $500 each:
Qualification confirmed before delivery. Intake disqualification rate: under 10%. Close rate: 17%. Cost per signed retainer: $3,000.
Same price per lead. $4,500–$5,300 difference in cost per signed retainer.
On 50 leads per month, that is $225,000–$265,000 in CPR difference — on the same $25,000 in lead spend.
Now the revenue side. A qualifying Roundup case settles for $100,000 to $500,000+. A qualifying AFFF case with a serious PFAS-linked cancer sits in a similar range. Mesothelioma can exceed $1,000,000.
Against those case values, a $3,000 CPR is not an acquisition cost. It’s a rounding error.
The firms losing money on mass tort leads are not paying too much per lead. They are paying for leads without real qualification and spending the difference on intake labor they cannot recover.
Frequently Asked Questions
Most firms reading this will recognize the situation — bad documentation, high disqualification rates, no visibility into the funnel. And they’ll keep buying from whoever they’re already buying from because switching vendors feels like more risk than staying.
The ones who switch will wonder why they waited.
Docket-Specific. OTP-Verified. One Firm.
Every mass tort lead qualified to the specific docket’s criteria before delivery. Product confirmed. Diagnosis confirmed. SOL verified. Full compliance documentation. No generic funnels.